{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:23:50Z","timestamp":1789885430074,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":1954,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1093\/annonc\/mdu264","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T18:18:24Z","timestamp":1410373104000},"page":"iii83-iii92","source":"Crossref","is-referenced-by-count":118,"special_numbering":"S3","title":["Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"25","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu264_bb0010","first-page":"233","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdu264_bb0015","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0020","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0025","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.1093\/annonc\/mdu264_bb0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu264_bb0040","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.14694\/EdBook_AM.2014.34.191","article-title":"Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches","volume":"34","author":"Dreyling","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1093\/annonc\/mdu264_bb0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0055","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"issue":"suppl. 4","key":"10.1093\/annonc\/mdu264_bb0060","first-page":"418","article-title":"Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease","volume":"19","author":"Engelhard","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0065","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu264_bb0070","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0075","article-title":"Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone\u201450 months update of the OSHO phase III study (OSHO#39)","volume":"19","author":"Herold","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":"Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu264_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu264_bb0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu264_bb0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu264_bb0100","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0110","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0115","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0120","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0125","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.V114.22.880.880","article-title":"Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma","volume":"114","author":"Hoster","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V120.21.151.151","volume":"120","author":"Hermine","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0135","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van 't Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu264_bb0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu264_bb0150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-013-1860-8","article-title":"Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC","volume":"93","author":"Touzeau","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdu264_bb0160","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu264_bb0170","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3109\/10428194.2013.825906","article-title":"High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial","volume":"55","author":"Laurell","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu264_bb0180","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood.V122.21.3367.3367","article-title":"Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma\u2014a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials","volume":"122","author":"Hoster","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V120.21.152.152","article-title":"Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study","volume":"120","author":"Le Gouill","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0190","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdu264_bb0195","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0200","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0205","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0210","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu264_bb0220","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu264_bb0225","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu264_bb0230","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0235","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu264_bb0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0245","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu264_bb0250","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0255","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0260","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu264_bb0265","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","article-title":"Treatment of younger patients with mantle cell lymphoma","volume":"48","author":"Harel","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mdu264_bb0270","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu264_bb0275","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0280","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood.V122.21.4384.4384","article-title":"Radioimmunotherapy in relapsed\/refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial","volume":"122","author":"Ferrero","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0285","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu264_bb0290","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K&dgr; inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0295","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V122.21.1789.1789","article-title":"The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients","volume":"122","author":"Davids","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0300","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0305","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","article-title":"Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation","volume":"19","author":"Cassaday","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdu264_bb0310","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","author":"Robinson","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdu264_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma\u2014the Lugano Classification","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"10.1093\/annonc\/mdu264_bb0320","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu264_bb0325","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdu264_bb0330","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/suppl_3\/iii83\/6679587\/mdu264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T04:29:02Z","timestamp":1582172942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341934092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":65,"alternative-id":["S092375341934092X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu264","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}